News for Prestige Consumer Healthcare Inc. (PBH)

On December 31, 2024, Macquarie Group Ltd (Trades, Portfolio) made a strategic decision to reduce its holdings in Prestige Consumer Healthcare Inc (PBH) by 365,

Revenue: $290.3 million, increased 2.7% year-over-year.EPS: Record quarterly EPS of $1.22, up 15% year-over-year.Gross Margin: Consistent in the low 30s, with

Feb 06, 2025 / 01:30PM GMTOperator Thank you for standing by and welcome to Prestige Consumer Healthcare third quarter, 2025 earnings conference call. At this t

Shares of Prestige Consumer Healthcare Inc (PBH) surged 10.93% in mid-day trading on Feb 6. The stock reached an intraday high of $84.51, before settling at $

Earnings Call Insights: Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q3 2025 Results Conference Call February 6, 2025 8:30 AM ETCompany ParticipantsPhil Terpolilli - Vice...

The headline numbers for Prestige Consumer Healthcare (PBH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 5.17% and 1.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Prestige Consumer Healthcare reports record third quarter results, with Q3 GAAP EPS beating by $0.06 and revenue beating by $3.17M.

On December 31, 2024, Dimensional Fund Advisors LP executed a strategic reduction in its holdings of Prestige Consumer Healthcare Inc. The transaction involved

The global dental floss market size is anticipated to grow from USD 600 million to USD 1074.50 million in 10 years. The market will experience rapid growth...

The bull market powered through the second quarter fueled by investor enthusiasm for artificial intelligence (AI) themed stocks.

Brandes Investment portfolio, holdings, 13F and news. Updated: 2024-06-06

The global eye drops market is growing at a CAGR of 5.3% during 2022–2030....

Tailoring wart therapeutics to individual patients based on factors like wart type, location, and responsiveness to previous treatments can lead to more...

/PRNewswire/ -- The

Read Investment Analysts’ Upgrades for May 10th (ADTN, AEL, ARLP, BAX, CLNE, CMA, CP, DMPZF, EADSY, EOG) at ETF Daily News

GuruFocus Article or News written by insider and the topic is about: